Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3June 21, 2019 7:30 AM Arrowhead Pharmaceuticals (ARWR) Treatment of Familial Chylomicronemia Syndrome Granted FDA Orphan StatusJune 20, 2019 4:04 PM